MEDXF - Medexus Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/03/2022
31/03/2021
31/03/2020
Total revenue
99,726
76,701
79,660
52,432
Cost of revenue
44,591
38,774
37,655
22,990
Gross profit
55,135
37,927
42,005
29,442
Operating expenses
Research development
3,044
5,873
4,596
1,098
Selling general and administrative
46,756
44,032
36,172
28,934
Total operating expenses
50,174
50,303
41,274
30,482
Operating income or loss
4,961
-12,376
731
-1,041
Interest expense
13,101
12,223
9,819
6,442
Total other income/expenses net
-522
20,779
-22,416
3,254
Income before tax
-8,662
-3,820
-31,501
-5,188
Income tax expense
2,260
-941
-3,237
-790.4386
Income from continuing operations
-10,922
-2,879
-28,264
-4,397
Net income
-10,922
-2,879
-28,264
-4,397
Net income available to common shareholders
-10,922
-2,879
-28,264
-4,397
Basic EPS
-
-0.15
-1.86
-0.33
Diluted EPS
-
-0.15
-1.86
-0.33
Basic average shares
-
19,454
15,197
14,360
Diluted average shares
-
19,454
15,197
14,360
EBITDA
-
14,548
-15,704
4,961